Mohammad Reza Hajian
1 
, Hamid Reza Jahantigh
2 , Shahrzad Alimohammadi
3,4 , Zahra Mojtahedi
5 , Neda Kianpour
6 , Majid Foroutan
7* 1 Nickan Research Institute, Isfahan, Iran
2 Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy
3 Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary
4 Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
5 School of Public Health, University of Nevada, Las Vegas, Nevada, USA
6 Department of Biotechnology, Inland Norway University of Applied Science, Hamar, Hedmark, Norway
7 Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
Implication for health policy/practice/research/medical education:
COVID-19 is a viral disease that first emerged in December 2019, Wuhan, China. In a short time, the disease spread and the world faced with a new pandemic. Since then, great effort implanted to produce effective vaccines and medications for the disease. Nirmatrelvir (PF07321332) is a new drug developed by Pfizer, Inc for COVID-19 treatment. In this essay, we stated recent findings about Nirmatrelvir.
Please cite this paper as: Hajian MR, Jahantigh HR, Alimohammadi S, Mojtahedi Z, Kianpour N, Foroutan M. Nirmatrelvir, a novel medication for COVID-19 treatment. J Nephropharmacol. 2023;12(1):e10486. DOI: 10.34172/npj.2021.10486.